StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) stock

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3086% above fair value
$286.01−6.81 (-2.33%)

Close on Nov 18, 2026Market cap $505.41BP/E 80.8Yield 2.33%

AbbVie gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

AbbVie's gross profit for the twelve months ending Jun 30, 2026 was $46.02B, up 11.2% year over year. For fiscal 2025 it was $42.96B, up 8.9% from the year before. Over ten years it grew 8.9% a year on average. The highest annual figure on record is $42.96B in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$42.96B+8.9%
FY2024Dec 31, 2024$39.43B+16.3%
FY2023Dec 31, 2023$33.90B-16.6%
FY2022Dec 31, 2022$40.64B+4.9%
FY2021Dec 31, 2021$38.75B+27.4%
FY2020Dec 31, 2020$30.42B+17.8%
FY2019Dec 31, 2019$25.83B+3.2%
FY2018Dec 31, 2018$25.04B+18.2%
FY2017Dec 31, 2017$21.17B+6.9%
FY2016Dec 31, 2016$19.81B+7.9%
FY2015Dec 31, 2015$18.36B+18.2%
FY2014Dec 31, 2014$15.53B+9.3%
FY2013Dec 31, 2013$14.21B+2.4%
FY2012Dec 31, 2012$13.87B+8.3%
FY2011Dec 31, 2011$12.81B–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.70B+14.6%
Q1 FY2026Mar 31, 2026$10.78B+15.4%
Q4 FY2025Dec 31, 2025$12.07B+12.7%
Q3 FY2025Sep 30, 2025$10.47B+2.2%
Q2 FY2025Jun 30, 2025$11.08B+8.0%
Q1 FY2025Mar 31, 2025$9.34B+13.7%
Q4 FY2024Dec 31, 2024$10.71B+24.5%
Q3 FY2024Sep 30, 2024$10.25B+37.7%
Q2 FY2024Jun 30, 2024$10.26B+6.6%
Q1 FY2024Mar 31, 2024$8.22B-0.3%
Q4 FY2023Dec 31, 2023$8.60B-21.5%
Q3 FY2023Sep 30, 2023$7.44B-24.0%
Q2 FY2023Jun 30, 2023$9.63B-7.6%
Q1 FY2023Mar 31, 2023$8.24B-13.1%
Q4 FY2022Dec 31, 2022$10.95B+3.6%
Q3 FY2022Sep 30, 2022$9.79B-1.6%
Q2 FY2022Jun 30, 2022$10.41B+10.4%
Q1 FY2022Mar 31, 2022$9.49B+7.8%
Q4 FY2021Dec 31, 2021$10.57B+15.2%
Q3 FY2021Sep 30, 2021$9.95B+26.7%
Q2 FY2021Jun 30, 2021$9.44B+40.5%
Q1 FY2021Mar 31, 2021$8.80B+31.8%
Q4 FY2020Dec 31, 2020$9.17B+37.0%
Q3 FY2020Sep 30, 2020$7.85B+19.7%
Q2 FY2020Jun 30, 2020$6.71B+4.3%
Q1 FY2020Mar 31, 2020$6.68B+8.9%
Q4 FY2019Dec 31, 2019$6.70B+6.6%
Q3 FY2019Sep 30, 2019$6.56B+2.5%
Q2 FY2019Jun 30, 2019$6.44B+1.5%
Q1 FY2019Mar 31, 2019$6.13B+2.1%
Q4 FY2018Dec 31, 2018$6.28B+15.1%
Q3 FY2018Sep 30, 2018$6.40B+19.0%
Q2 FY2018Jun 30, 2018$6.34B+17.2%
Q1 FY2018Mar 31, 2018$6.01B+22.0%
Q4 FY2017Dec 31, 2017$5.46B+4.1%
Q3 FY2017Sep 30, 2017$5.38B+9.2%
Q2 FY2017Jun 30, 2017$5.42B–
Q1 FY2017Mar 31, 2017$4.92B–
Q4 FY2016Dec 31, 2016$5.24B–
Q3 FY2016Sep 30, 2016$4.93B–

More AbbVie figures

See a number that looks wrong?